Events & Presentations Events & Presentations Latest Corporate Presentation September 22, 2021 Checkmate Pharmaceuticals Corporate Overview – September 2021 Upcoming Events Cantor Virtual Global Healthcare Conference Sep 30, 2021 at 10:40 AM EDT Add to Outlook Add to Google Calendar Past Events H.C. Wainwright 23rd Annual Global Investment Conference Sep 13, 2021 at 7:00 AM EDT BTIG Virtual Biotechnology Conference Aug 9, 2021 at 3:30 PM EDT Jefferies 2021 Virtual Healthcare Conference Jun 1, 2021 at 2:00 PM EDT Bank of America Securities 2021 Virtual Healthcare Conference May 12, 2021 at 1:15 PM EDT Jefferies London 2020 Virtual Healthcare Conference Nov 17, 2020 Supporting Materials Checkmate Pharmaceuticals Corporate Overview- November 2020 880.5 KB Presentations ASCO 2021. Wong, Deborah, et al. Source Abstract TPS6089. CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab … View poster: CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + p… World Congress of Melanoma/EADO Congress 2021. Krieg, Art. View presentation recording: CMP-001, a CpG-A TLR9 agonist package in a virus-l… World Congress of Melanoma/EADO Congress 2021. Diwakar, Davar. View presentation: Neoadjuvant combinations with innate immunity stimulation World Congress of Melanoma/EADO Congress 2021. Ribas, Antoni, et al. Source Abstract P-119. View poster: CMP-001-010: An Open-Label, Phase 2 Study to Evaluate Intratumoura… World Congress of Melanoma/EADO Congress 2021. Davar, Diwakar, et al. Source Abstract P-074. View poster: CMP-001-011: First-Line Vidutolimod (CMP-001) Plus Nivolumab Versu… AACR 2021. Luke, Jason, et al. Source Abstract 5231. Vidutolimod (CMP-001) demonstrates improved response in noninflamed anti–PD-1 r… View slides: Vidutolimod (CMP-001) demonstrates improved response in noninflame… View presentation recording: Vidutolimod (CMP-001) demonstrates improved respon… SITC 2020. Davar, Diwakar, et al. Source Abstract 612. View poster: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (… View slides: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (… SITC 2020. Morris, Aaron, et al. Source Abstract 604. View poster: Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist d… SITC 2020. Milhem, Mohammed, et al. Source Abstract 579. Video: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist… View poster: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) a… SITC 2019. Kirkwood, John, et al. Source Abstract 11548/085. Durable responses in anti-PD-1 refractory melanoma following intra-tumoral inje… View slides: Durable responses in anti-PD-1 refractory melanoma following intra… Pagination Current page 1 Page 2 Next page next › Last page last »
Events & Presentations Latest Corporate Presentation September 22, 2021 Checkmate Pharmaceuticals Corporate Overview – September 2021 Upcoming Events Cantor Virtual Global Healthcare Conference Sep 30, 2021 at 10:40 AM EDT Add to Outlook Add to Google Calendar Past Events H.C. Wainwright 23rd Annual Global Investment Conference Sep 13, 2021 at 7:00 AM EDT BTIG Virtual Biotechnology Conference Aug 9, 2021 at 3:30 PM EDT Jefferies 2021 Virtual Healthcare Conference Jun 1, 2021 at 2:00 PM EDT Bank of America Securities 2021 Virtual Healthcare Conference May 12, 2021 at 1:15 PM EDT Jefferies London 2020 Virtual Healthcare Conference Nov 17, 2020 Supporting Materials Checkmate Pharmaceuticals Corporate Overview- November 2020 880.5 KB Presentations ASCO 2021. Wong, Deborah, et al. Source Abstract TPS6089. CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab … View poster: CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + p… World Congress of Melanoma/EADO Congress 2021. Krieg, Art. View presentation recording: CMP-001, a CpG-A TLR9 agonist package in a virus-l… World Congress of Melanoma/EADO Congress 2021. Diwakar, Davar. View presentation: Neoadjuvant combinations with innate immunity stimulation World Congress of Melanoma/EADO Congress 2021. Ribas, Antoni, et al. Source Abstract P-119. View poster: CMP-001-010: An Open-Label, Phase 2 Study to Evaluate Intratumoura… World Congress of Melanoma/EADO Congress 2021. Davar, Diwakar, et al. Source Abstract P-074. View poster: CMP-001-011: First-Line Vidutolimod (CMP-001) Plus Nivolumab Versu… AACR 2021. Luke, Jason, et al. Source Abstract 5231. Vidutolimod (CMP-001) demonstrates improved response in noninflamed anti–PD-1 r… View slides: Vidutolimod (CMP-001) demonstrates improved response in noninflame… View presentation recording: Vidutolimod (CMP-001) demonstrates improved respon… SITC 2020. Davar, Diwakar, et al. Source Abstract 612. View poster: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (… View slides: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (… SITC 2020. Morris, Aaron, et al. Source Abstract 604. View poster: Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist d… SITC 2020. Milhem, Mohammed, et al. Source Abstract 579. Video: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist… View poster: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) a… SITC 2019. Kirkwood, John, et al. Source Abstract 11548/085. Durable responses in anti-PD-1 refractory melanoma following intra-tumoral inje… View slides: Durable responses in anti-PD-1 refractory melanoma following intra… Pagination Current page 1 Page 2 Next page next › Last page last »
Cantor Virtual Global Healthcare Conference Sep 30, 2021 at 10:40 AM EDT Add to Outlook Add to Google Calendar
Jefferies London 2020 Virtual Healthcare Conference Nov 17, 2020 Supporting Materials Checkmate Pharmaceuticals Corporate Overview- November 2020 880.5 KB
ASCO 2021. Wong, Deborah, et al. Source Abstract TPS6089. CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab … View poster: CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + p…
CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab … View poster: CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + p…
World Congress of Melanoma/EADO Congress 2021. Krieg, Art. View presentation recording: CMP-001, a CpG-A TLR9 agonist package in a virus-l…
World Congress of Melanoma/EADO Congress 2021. Diwakar, Davar. View presentation: Neoadjuvant combinations with innate immunity stimulation
World Congress of Melanoma/EADO Congress 2021. Ribas, Antoni, et al. Source Abstract P-119. View poster: CMP-001-010: An Open-Label, Phase 2 Study to Evaluate Intratumoura…
World Congress of Melanoma/EADO Congress 2021. Davar, Diwakar, et al. Source Abstract P-074. View poster: CMP-001-011: First-Line Vidutolimod (CMP-001) Plus Nivolumab Versu…
AACR 2021. Luke, Jason, et al. Source Abstract 5231. Vidutolimod (CMP-001) demonstrates improved response in noninflamed anti–PD-1 r… View slides: Vidutolimod (CMP-001) demonstrates improved response in noninflame… View presentation recording: Vidutolimod (CMP-001) demonstrates improved respon…
Vidutolimod (CMP-001) demonstrates improved response in noninflamed anti–PD-1 r… View slides: Vidutolimod (CMP-001) demonstrates improved response in noninflame… View presentation recording: Vidutolimod (CMP-001) demonstrates improved respon…
SITC 2020. Davar, Diwakar, et al. Source Abstract 612. View poster: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (… View slides: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (…
View poster: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (… View slides: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (…
SITC 2020. Morris, Aaron, et al. Source Abstract 604. View poster: Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist d…
SITC 2020. Milhem, Mohammed, et al. Source Abstract 579. Video: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist… View poster: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) a…
Video: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist… View poster: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) a…
SITC 2019. Kirkwood, John, et al. Source Abstract 11548/085. Durable responses in anti-PD-1 refractory melanoma following intra-tumoral inje… View slides: Durable responses in anti-PD-1 refractory melanoma following intra…
Durable responses in anti-PD-1 refractory melanoma following intra-tumoral inje… View slides: Durable responses in anti-PD-1 refractory melanoma following intra…
